PE20040866A1 - Formas cristalinas de [4-carbamoil-1-(3-fluorobencil)-2,7-dihidroxi-7-metil-octil]-amida del acido quinoxalina-2-carboxilico - Google Patents

Formas cristalinas de [4-carbamoil-1-(3-fluorobencil)-2,7-dihidroxi-7-metil-octil]-amida del acido quinoxalina-2-carboxilico

Info

Publication number
PE20040866A1
PE20040866A1 PE2003000794A PE2003000794A PE20040866A1 PE 20040866 A1 PE20040866 A1 PE 20040866A1 PE 2003000794 A PE2003000794 A PE 2003000794A PE 2003000794 A PE2003000794 A PE 2003000794A PE 20040866 A1 PE20040866 A1 PE 20040866A1
Authority
PE
Peru
Prior art keywords
ocyl
carbamoil
fluorobenzyl
quinoxaline
dihydroxy
Prior art date
Application number
PE2003000794A
Other languages
English (en)
Inventor
John Charles Kath
Zheng Jane Li
Christopher Stanley Poss
Eric Brock Mcelroy
Clifford Nathaniel Meltz
Zhengong Bryan Li
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20040866A1 publication Critical patent/PE20040866A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A UNA FORMA CRISTALINA DE [4-CARBAMOIL-1-(3-FLUOROBENCIL)-2,7-DIHIDROXI-7-METIL-OCTIL]-AMIDA DEL ACIDO QUINOXALINA-2-CARBOXILICO QUE COMPRENDE LAS FORMAS A, B, C, ENTRE OTROS DONDE A TIENE UN MODELO DE DIFRACCION DE RAYOS X EN POLVO EXPRESADO EN GRADOS DOS-THETA DE 5,1; 8,8; 10,1; 13,3; 15,1; ENTRE OTROS Y UN ESPECTRO DE RMN EN ESTADO SOLIDO DE 182,5; 166,2; 165,2; ENTRE OTROS; B TIENE UN MODELO DE DIFRACCION DE RAYOS X EN POLVO EXPRESADO EN GRADOS DOS-THETA DE 6,0; 7,4; 11,0; 13,8; ENTRE OTROS Y UN ESPECTRO DE RMN EN ESTADO SOLIDO DE 177,9; 165,7; 163,4; 161,4; ENTRE OTROS. SE REFIERE TAMBIEN A UN METODO DE PREPARACION Y SON UTILES EN EL TRATAMIENTO O PREVENCION DE ENFERMEDADES AUTOINMUNES, ESTADOS INFLAMATORIOS AGUDOS Y CRONICOS, ESTADOS ALERGICOS, ENTRE OTROS
PE2003000794A 2002-08-12 2003-08-08 Formas cristalinas de [4-carbamoil-1-(3-fluorobencil)-2,7-dihidroxi-7-metil-octil]-amida del acido quinoxalina-2-carboxilico PE20040866A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40321602P 2002-08-12 2002-08-12

Publications (1)

Publication Number Publication Date
PE20040866A1 true PE20040866A1 (es) 2004-11-26

Family

ID=31715961

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000794A PE20040866A1 (es) 2002-08-12 2003-08-08 Formas cristalinas de [4-carbamoil-1-(3-fluorobencil)-2,7-dihidroxi-7-metil-octil]-amida del acido quinoxalina-2-carboxilico

Country Status (22)

Country Link
US (1) US20040072834A1 (es)
EP (1) EP1539715A1 (es)
JP (1) JP2005538130A (es)
AP (1) AP2005003226A0 (es)
AR (1) AR040839A1 (es)
AU (1) AU2003250450A1 (es)
BR (1) BR0313378A (es)
CA (1) CA2494776A1 (es)
EC (1) ECSP055588A (es)
GT (1) GT200300169A (es)
IL (1) IL166548A0 (es)
IS (1) IS7674A (es)
MX (1) MXPA05001781A (es)
NO (1) NO20050540L (es)
OA (1) OA12894A (es)
PA (1) PA8580401A1 (es)
PE (1) PE20040866A1 (es)
TN (1) TNSN05035A1 (es)
TW (1) TW200407316A (es)
UY (1) UY27928A1 (es)
WO (1) WO2004014875A1 (es)
ZA (1) ZA200500768B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY33110A (es) 2009-12-23 2011-07-29 Ironwood Pharmaceuticals Inc Moduladores de CRTH2
WO2012009134A1 (en) 2010-07-12 2012-01-19 Ironwood Pharmaceuticals, Inc. Crth2 modulators
WO2012009137A1 (en) 2010-07-12 2012-01-19 Ironwood Pharmaceuticals, Inc. Crth2 modulators
CN102276539B (zh) * 2011-06-29 2013-08-14 赵雪梅 一种具有抑菌作用的化合物及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE640616A (es) * 1962-12-19
US3492397A (en) * 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US4060598A (en) * 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
US3538214A (en) * 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US4173626A (en) * 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
US6403587B1 (en) * 1997-02-26 2002-06-11 Pfizer Inc. Heteroaryl-hexanoic acid amide derivatives, their preparation and their use as selective inhibitors of MIP-1-α binding to its CCR 1 receptor
UA57824C2 (uk) * 1998-02-05 2003-07-15 Пфайзер Продактс Інк. Похідні дигідроксигексанової кислоти, фармацевтична композиція, що їх містить (варіанти), та спосіб лікування (варіанти)

Also Published As

Publication number Publication date
ZA200500768B (en) 2006-07-26
IL166548A0 (en) 2006-01-15
MXPA05001781A (es) 2005-04-25
JP2005538130A (ja) 2005-12-15
TNSN05035A1 (fr) 2007-05-14
OA12894A (en) 2006-10-13
EP1539715A1 (en) 2005-06-15
CA2494776A1 (en) 2004-02-19
US20040072834A1 (en) 2004-04-15
GT200300169A (es) 2004-05-12
IS7674A (is) 2005-01-27
PA8580401A1 (es) 2004-02-16
UY27928A1 (es) 2004-03-31
BR0313378A (pt) 2005-07-12
AU2003250450A1 (en) 2004-02-25
AP2005003226A0 (en) 2005-03-31
AR040839A1 (es) 2005-04-20
WO2004014875A1 (en) 2004-02-19
ECSP055588A (es) 2005-04-18
NO20050540L (no) 2005-03-10
TW200407316A (en) 2004-05-16

Similar Documents

Publication Publication Date Title
WO2005063734A3 (de) Substituierte thiophene
HUP0402485A2 (hu) A clopidogrel hidrogénszulfát polimorf módosulatai
PE20040866A1 (es) Formas cristalinas de [4-carbamoil-1-(3-fluorobencil)-2,7-dihidroxi-7-metil-octil]-amida del acido quinoxalina-2-carboxilico
ITRM20020277A0 (it) Muteine del fattore di crescita placentare tipo 1, metodo di preparazione e loro applicazioni.
EP1580660A3 (en) Node matching in a dynamic, decentralized environment
BRPI0412707A (pt) partìculas contendo um agente ativo na forma de um coprecipitado
FR2842802B1 (fr) Procede de fabrication du 1,1-difluoroethane et application a la fabrication du 1,1-difluoroethylene
TH58957EX (th) ลัง
JP2007070312A5 (es)
TH81860EX (th) ชิ้นส่วนสิ่งก่อสร้างสำเร็จรูป
TH59960EX (th) อุปกรณ์ซักผ้าด้วยมือ
TH59546EX (th) แหวน
TH59447EX (th) แหวน
AU2003302847A1 (en) Chip-on-film and its methods of manufacturing by electro-forming
TH56957EX (th) พาน
TH57953EX (th) บล็อกสำเร็จรูป
TH56256EX (th) ชิ้นส่วนที่นั่ง
TH71223S (th) บานตู้
TH71222S (th) บานตู้
RU2002108574A (ru) Способ обработки алюминиевых сплавов
TH56784EX (th) พาน
TH58281EX (th) แปรงสีฟัน
TH58282EX (th) แปรงสีฟัน
TH61567S (th) แหวน
RU2002119749A (ru) Способ устранения рубцовых изменений кожи лица

Legal Events

Date Code Title Description
FC Refusal